Brief: Eiger Biopharmaceuticals Announces First Patient Enrolled In LIMT-2 A Phase 3 Study Of Peginterferon Lambda In Patients With Chronic Hepatitis Delta Virus Infection
21/12/2021 21:17
Dec 21 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED
IN
LIMT-2: A PHASE 3 STUDY OF PEGINTERFERON LAMBDA IN PATIENTS WITH
CHRONIC HEPATITIS DELTA VIRUS INFECTION
Source text for Eikon: ID:nPn78tHGFa
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview